| 产品描述: | Irsenontrine (E2027) is an orally active and selective phosphodiesterase 9 (PDE9) inhibitor. Irsenontrine can be used for the research of neurological diseases. |
| 体外研究: |
Irsenontrine (0.3, 3.3 mg/kg; p.o.) exhibits a significant ameliorative effect on the percentage of exploration of the novel object at 3.3 mg/kg in Scopolamine-induced rats[1]. Irsenontrine (1 mg/kg; p.o.) and memantine hydrochloride (1 mg/kg; p.o.) combined treatment group exhibits a significantly higher percentage of exploration of the novel object than memantine hydrochloride (1 mg/kg) alone[1]. |
| 体内研究: |
Irsenontrine (E2027) is an orally active and selective phosphodiesterase 9 (PDE 9) inhibitor. |
| 参考文献: |
1. Miyamoto, et al. Dementia therapeutic agent combining pyrazoloquinoline derivative and memantine. WO2018221550 A1 2. Hershey LA, et al. Pharmacological Management of Dementia with Lewy Bodies. Drugs Aging. 2019;36(4):309-319. 3. Eisai to present latest research on Alzheimer’s disease / dementia pipeline at the 14th international conference on Alzheimer’s & Parkinson’s diseases |
| 保存条件: |
2-8°C, 避光, 干燥 |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
2.561 ml |
12.806 ml |
25.612 ml |
| 5 mM |
0.512 ml |
2.561 ml |
5.122 ml |
| 10 mM |
0.256 ml |
1.281 ml |
2.561 ml |
| 50 mM |
0.051 ml |
0.256 ml |
0.512 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |